Skip to content
OpenCapital
Get started

Ionis Pharmaceuticals IONS Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——
Roivant Sciences logo
Roivant SciencesROIV
——
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
——

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
Ionis Pharmaceuticals (IONS) reported accretion (amortization) of discounts and premiums, investments of $6.19M in Q1 2026.
How has Ionis Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
Ionis Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 12.9% year-over-year, from $7.11M to $6.19M.
What is the long-term trend for Ionis Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
Over 3 years (2021 to 2025), Ionis Pharmaceuticals's accretion (amortization) of discounts and premiums, investments has grown at a 10.1% compound annual growth rate (CAGR), from -$17.78M to $23.74M.
What does accretion (amortization) of discounts and premiums, investments mean?
Non-cash adjustments to the value of investment holdings based on their purchase price relative to par value.
How do you interpret accretion (amortization) of discounts and premiums, investments?
Changes reflect the composition and maturity profile of the company's investment portfolio.
How does accretion (amortization) of discounts and premiums, investments compare across companies?
Common for companies with significant cash reserves invested in debt securities.